Discovery, Synthesis, and Evaluation of Highly Selective Vascular Endothelial Growth Factor Receptor 3 (VEGFR3) Inhibitor for the Potential Treatment of Metastatic Triple-Negative Breast Cancer

Targeting Bromodomain and Extraterminal Proteins for Drug Discovery: From Current Progress to Technological Development

(2021) Pan Tang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Cancer statistics, 2020

(2020) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Acetylene Group, Friend or Foe in Medicinal Chemistry

(2020) Tanaji T. Talele   JOURNAL OF MEDICINAL CHEMISTRY

Discovery of a Novel Dual-Target Inhibitor of ERK1 and ERK5 That Induces Regulated Cell Death to Overcome Compensatory Mechanism in Specific Tumor Types

(2020) Guan Wang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Human Tumor‐Lymphatic Microfluidic Model Reveals Differential Conditioning of Lymphatic Vessels by Breast Cancer Cells

(2020) Jose M. Ayuso et al.   Advanced Healthcare Materials

Assessing breast lymphoedema following breast cancer treatment using indocyanine green lymphography

(2020) Asha Heydon-White et al.   BREAST CANCER RESEARCH AND TREATMENT

Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer

(2020) Vicky Makker et al.   JOURNAL OF CLINICAL ONCOLOGY

Soluble Vegfr3 gene therapy suppresses multi‐organ metastasis in a mouse mammary cancer model

(2020) Masa‐Aki Shibata et al.   CANCER SCIENCE

Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial

(2020) Yi-Zhou Jiang et al.   CELL RESEARCH

Design, synthesis, and biological evaluation of quinazolin-4(3H)-one derivatives co-targeting poly(ADP-ribose) polymerase-1 and bromodomain containing protein 4 for breast cancer therapy

(2020) Xiaosa Chang et al.   Acta Pharmaceutica Sinica B

Targeting Atg4B for cancer therapy: Chemical mediators

(2020) Gaoxia Yang et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Designing an eEF2K-Targeting PROTAC small molecule that induces apoptosis in MDA-MB-231 cells

(2020) Yao Liu et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Proteolysis-targeting chimeras in breast cancer therapy

(2020) Jifa Zhang et al.   Future Medicinal Chemistry

Fucoxanthin inhibits tumour-related lymphangiogenesis and growth of breast cancer

(2019) Jia Wang et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Multikinase inhibitor motesanib enhances the antitumor effect of cisplatin in cisplatin‑resistant human bladder cancer cells via apoptosis and the PI3K/Akt pathway

(2019) Jin‑Nyoung Ho et al.   ONCOLOGY REPORTS

Evaluation of Local Injection of Bevacizumab against Triple-Negative Breast Cancer Xenograft Tumors

(2019) Xin Jiang et al.   CURRENT PHARMACEUTICAL DESIGN

Regulation of Blood and Lymphatic Vessels by Immune Cells in Tumors and Metastasis

(2019) Massimiliano Mazzone et al.   Annual Review of Physiology

Activation of the VEGFC/VEGFR3 pathway induces tumor immune escape in colorectal cancer

(2019) Carlotta Tacconi et al.   CANCER RESEARCH

Sorafenib-Induced Apoptosis in Hepatocellular Carcinoma Is Reversed by SIRT1

(2019) Antje Garten et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials

(2019) Ann Lin et al.   Science Translational Medicine

Identification of a Unique Resorcylic Acid Lactone Derivative That Targets Both Lymphangiogenesis and Angiogenesis

(2019) Youngsun Han et al.   JOURNAL OF MEDICINAL CHEMISTRY

Docetaxel facilitates lymphatic-tumor crosstalk to promote lymphangiogenesis and cancer progression

(2018) Alexandra R. Harris et al.   BMC CANCER

Telatinib Is an Effective Targeted Therapy for Pseudomyogenic Hemangioendothelioma

(2018) David G.P. van IJzendoorn et al.   CLINICAL CANCER RESEARCH

Design, synthesis and structure-activity relationship of a focused library of β-phenylalanine derivatives as novel eEF2K inhibitors with apoptosis-inducing mechanisms in breast cancer

(2018) Yongzhi Guo et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Small-Molecule Activator of UNC-51-Like Kinase 1 (ULK1) That Induces Cytoprotective Autophagy for Parkinson’s Disease Treatment

(2018) Liang Ouyang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Identification of ILK as a critical regulator of VEGFR3 signalling and lymphatic vascular growth

(2018) Sofia Urner et al.   EMBO JOURNAL

Podoplanin+ tumor lymphatics are rate limiting for breast cancer metastasis

(2018) Yang Chen et al.   PLOS BIOLOGY

How to train your inhibitor: Design strategies to overcome resistance to Epidermal Growth Factor Receptor inhibitors

(2017) Sandra N. Milik et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

The role of Cediranib in ovarian cancer

(2017) Cecilia Orbegoso et al.   EXPERT OPINION ON PHARMACOTHERAPY

Discovery of a Small-Molecule Bromodomain-Containing Protein 4 (BRD4) Inhibitor That Induces AMP-Activated Protein Kinase-Modulated Autophagy-Associated Cell Death in Breast Cancer

(2017) Liang Ouyang et al.   JOURNAL OF MEDICINAL CHEMISTRY

De Novo Computational Design for Development of a Peptide Ligand Oriented to VEGFR-3 with High Affinity and Long Circulation

(2017) Hong M. Li et al.   MOLECULAR PHARMACEUTICS

Discovery of a small molecule targeting ULK1-modulated cell death of triple negative breast cancer in vitro and in vivo

(2017) Lan Zhang et al.   Chemical Science

In Vitro and In Vivo Activity of Lucitanib in FGFR1/2 Amplified or Mutated Cancer Models

(2017) Federica Guffanti et al.   NEOPLASIA

Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer

(2016) Muhammad Wasif Saif et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Antitumor Response of VEGFR2- and VEGFR3-Amplified Angiosarcoma to Pazopanib

(2016) Vinod Ravi et al.   Journal of the National Comprehensive Cancer Network

Antiangiogenic therapy in oncology: current status and future directions

(2016) Gordon C Jayson et al.   LANCET

Utilizing Zebrafish to Identify Anti-(Lymph)Angiogenic Compounds for Cancer Treatment: Promise and Future Challenges

(2016) Kazuhide S. Okuda et al.   MICROCIRCULATION

Macrophage-Induced Lymphangiogenesis and Metastasis following Paclitaxel Chemotherapy Is Regulated by VEGFR3

(2016) Dror Alishekevitz et al.   Cell Reports

Novel peptides suppress VEGFR-3 activity and antagonize VEGFR-3-mediated oncogenic effects

(2015) Yi-Wen Chang et al.   Oncotarget

SAR131675, a Potent and Selective VEGFR-3-TK Inhibitor with Antilymphangiogenic, Antitumoral, and Antimetastatic Activities

(2012) A. Alam et al.   MOLECULAR CANCER THERAPEUTICS

A deeper understanding of VEGFR inhibitors

(2012) Charlotte Harrison   NATURE REVIEWS DRUG DISCOVERY

Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors

(2012) M. McTigue et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Vascular endothelial growth factor receptor-3 promotes breast cancer cell proliferation, motility and survival in vitro and tumor formation in vivo

(2011) Elena V. Kurenova et al.   CELL CYCLE

Lymphangiogenesis: Molecular Mechanisms and Future Promise

(2010) Tuomas Tammela et al.   CELL

Vascular Endothelial Growth Factor Receptors VEGFR-2 and VEGFR-3 Are Localized Primarily to the Vasculature in Human Primary Solid Cancers

(2010) N. R. Smith et al.   CLINICAL CANCER RESEARCH

Small Molecule Chloropyramine Hydrochloride (C4) Targets the Binding Site of Focal Adhesion Kinase and Vascular Endothelial Growth Factor Receptor 3 and Suppresses Breast Cancer Growth in Vivo

(2009) Elena V. Kurenova et al.   JOURNAL OF MEDICINAL CHEMISTRY